Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia

We present retrospective data on 140 patients treated with mCBAD (a high-dose modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone regimen) at our institution. More than 80% (120/140 patients) of patients received ≤2 cycles of mCBAD with best overall response ≥90% (very good partial response 18%-23%, and complete remission 7%-23%). Median overall survival from start date of mCBAD and treatment-related mortality were 14 months for relapsed patients: 8% (10/116; n = 116), 16 months for plasma cell leukemia: 9% (1/11; n = 11), and 35 months for newly diagnosed myeloma: 0% (n = 13). mCBAD response is short-lived and has high treatment-related mortality. It might be useful as a bridge to transplantation or cell therapies when other treatments are not available.